Discovery of Potent Peptide-Mimetic Antagonists for the Human Thrombin Receptor, Protease-Activated Receptor-1 (PAR-1)
Current Medicinal Chemistry-Cardiovascular & Hematological Agents · 2003
DOI: 10.2174/1568016033356724 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Medicinal Chemistry-Cardiovascular & Hematological Agents, 2003. Verfasst von Bruce E Maryanoff und 3 weiteren Autor:innen. Beteiligte Einrichtung: Drug Discovery, Johnson & Johnson Pharmaceutical Research & Development, Spring House, Pennsylvania 19477-0776, USA. bmaryano@prdus.jnj.com. Hauptthemen laut MEDLINE: Drug Design, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 27-mal zitiert (Crossref).
Abstract (Originalsprache)
Protease-activated receptors (PARs) represent a unique family of seven-transmembrane G-protein-coupled receptors, which are enzymatically cleaved to expose a new extracellular N-terminus that acts as a tethered activating ligand. PAR-1 is cleaved and activated by the serine protease alpha-thrombin, is expressed in various tissues (e.g. platelets and vascular cells), and is involved in cellular responses associated with hemostasis, proliferation, and tissue injury. By using a de novo design approach, we have discovered a series of potent heterocycle-based peptide-miimetic antagonists of PAR-1, exemplified by advanced leads RWJ-56110 (22) and RWJ-58259 (32). These compounds are potent, selective PAR-1 antagonists, devoid of PAR-1 agonist and thrombin inhibitory activity: they bind to PAR-1, interfere with calcium mobilization and cellular functions associated with PAR-1, and do not affect PAR-2, PAR-3, or PAR-4. RWJ-56110 was determined to be a direct inhibitor of PAR-1 activation and internalization, without affecting PAR-1 N-terminal cleavage. At high concentrations of alpha-thrombin, RWJ-56110 fully blocked activation responses in human vascular cells, but not in human platelets; whereas, at high concentrations of TRAP-6, RWJ-56110 blocked activation responses in both cell types. This result is consistent with the presence of another thrombin receptor on human platelets, namely PAR-4. RWJ-56110 and RWJ-58259 clearly interrupt the binding of a tethered ligand to its receptor. RWJ-58259 demonstrated antirestenotic activity in a rat balloon angioplasty model and antithrombotic activity in a cynomolgus monkey arterial injury model. Such PAR-1 antagonists should not only serve as useful tools to delineate the physiological and pathophysiological roles of PAR-1, but also may have therapeutic potential for treating thrombosis and restenosis in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Drug Discovery, Johnson & Johnson Pharmaceutical Research & Development, Spring House, Pennsylvania 19477-0776, USA. bmaryano@prdus.jnj.com
Zitieren
APA
Maryanoff, B. E., Zhang, H. C., Andrade-Gordon, P., & Derian, C. K. (2003). Discovery of Potent Peptide-Mimetic Antagonists for the Human Thrombin Receptor, Protease-Activated Receptor-1 (PAR-1). Current Medicinal Chemistry-Cardiovascular & Hematological Agents. https://doi.org/10.2174/1568016033356724
Vancouver
Maryanoff BE, Zhang HC, Andrade-Gordon P, Derian CK. Discovery of Potent Peptide-Mimetic Antagonists for the Human Thrombin Receptor, Protease-Activated Receptor-1 (PAR-1). Current Medicinal Chemistry-Cardiovascular & Hematological Agents. 2003. doi:10.2174/1568016033356724
BibTeX
@article{Maryanoff2003,
author = {Maryanoff, Bruce E and Zhang, Han-Cheng and Andrade-Gordon, Patricia and Derian, Claudia K},
title = {Discovery of Potent Peptide-Mimetic Antagonists for the Human Thrombin Receptor, Protease-Activated Receptor-1 (PAR-1)},
journal = {Current Medicinal Chemistry-Cardiovascular & Hematological Agents},
year = {2003},
doi = {10.2174/1568016033356724}
}
EUVIMED